The UK pharmaceutical sector generates a trade surplus in excess of £5 billion per annum. Furthermore, it is estimated that the UK pharmaceutical sector invests £13.3 million in R&D every day. Current figures show that this sector employs 72,000 employees with 27,000 of those working exclusively in R&D. With these impressive statistics, it is no wonder that the pharmaceutical sector is UK’s most successful research-based industry. There are however, many challenges facing the pharmaceutical sector, most noticeably increased customer expectation and poor scientific productivity. With patents expiring, increased public scrutiny and budgetary challenges, this industry is at a crossroads. It has been suggested that for every 25,000 compounds that start in the laboratory, 25 will be tested on humans and perhaps only 5 will ever make it to market. The methodology adopted for new drug development is well established and can be broken down into four distinct stages: drug discovery, preclinical development, clinical development and post launch. In each of these stages pharmaceutical companies will be undertaking qualifying R&D activities.
Examples of eligible R&D activities:
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.